All In Biotech

Drug Trial Radar · NCT04121455

Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients

Single-arm, Dose-escalation Phase 1/2 Study of Olaptesed Pegol (NOX-A12) in Combination With Irradiation in Inoperable or Partially Resected First-line Glioblastoma Patients With Unmethylated MGMT Promoter With a Multiple-arm Expansion Group

Last checked: Nov 19, 2026Latest source record: Jun 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 117 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

117

Planned (sponsor's estimate)

Start

Sep 12, 2019

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Lead sponsor
TME Pharma AGIndustry
Sponsor type
Industry
First posted
Oct 10, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to obtain first, exploratory information on the safety and efficacy of (i) olaptesed pegol in combination with radiation therapy in patients with newly diagnosed glioblastoma of unmethylated MGMT promoter status either not amenable to resection (biopsy only) or after incomplete tumor resection, and (ii) olaptesed pegol in combination with radiation therapy and bevacizumab in patients with newly diagnosed glioblastoma of unmethylated MGMT promoter status either not amenable to resection (biopsy only) or after incomplete or complete tumor resection. Further arms are included (i) to establish safety for the combination of olaptesed pegol at three different doses in addition to radiotherapy and bevacizumab, (ii) to explore the benefit of combining olaptesed pegol at different dose levels with bevacizumab in order to define the doses to move forward into a subsequent randomized dose-finding study, (iii) to explore the contribution of the therapy components olaptesed pegol and bevacizumab to patient benefit and (iv) to put the clinical outcome of these treatment regimens into perspective with the standard of care treatment with temozolomide and radiotherapy.

Conditions

  • Glioblastoma

Interventions

  • Olaptesed pegolDrug

    Olaptesed pegol continuous i.v. administration

  • RadiotherapyRadiation

    Radiotherapy in weeks 1-6; cumulative dose of 60 Gy in 2 Gy fractions

  • BevacizumabDrug

    Bevacizumab every 2 weeks i.v. infusion

  • PembrolizumabDrug

    Pembrolizumab every 3 weeks i.v. for 26 weeks

  • Temozolomide (TMZ)Drug

    oral treatment according to current SPC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety - Number of patients with treatment-related adverse events as assessed by CTCAETime frame: through study completion, an average of 3 years

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Klinik und Poliklinik für Neurologie Schwerpunkt Klinische Neuroonkologie

    Bonn, Germany

  • Klinik für Neurologie

    Essen, Germany

  • Klinik für Strahlentherapie und Radioonkologie

    Leipzig, Germany

  • Klinik für Strahlentherapie und Radioonkologie

    Mannheim, Germany

  • Klinik für Neurologie mit Institut für Translationale Neurologie

    Münster, Germany

  • Abteilung Neurologie mit interdisziplinärem Schwerpunkt Neuroonkologie

    Tübingen, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.